questionText: To ask the Secretary of State for Health and Social Care, what his planned timetable is for when patients with Myasthenia Gravis will have access to recently licenced products.
answerText: On 7 March 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the medicine rozanolixizumab, marketed as Rystiggo, to treat adults with generalised myasthenia gravis.The National Institute for Health and Care Excellence (NICE) ev...
heading: Myasthenia Gravis: Medical Treatments